Sienna Gestion Sells 30,795 Shares of Pfizer Inc. (NYSE:PFE)

Key Points

• Sienna Gestion sold 30,795 shares of Pfizer Inc., decreasing its position by 11.9%, and now holds 228,331 shares valued at approximately $5.62 million.
• Pfizer's most recent earnings report revealed an EPS of $0.78, surpassing the consensus estimate by $0.20, alongside a revenue of $14.65 billion.
• The company declared a quarterly dividend of $0.43, which will yield an annualized dividend of $1.72 and a dividend yield of 6.8% for shareholders.

Sienna Gestion reduced its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 11.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 228,331 shares of the biopharmaceutical company's stock after selling 30,795 shares during the period. Sienna Gestion's holdings in Pfizer were worth $5,624,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of PFE. Clarity Asset Management Inc. bought a new stake in Pfizer during the 4th quarter valued at about $27,000. Gould Capital LLC increased its stake in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. GKV Capital Management Co. Inc. bought a new stake in Pfizer during the 1st quarter valued at about $27,000. Bayforest Capital Ltd bought a new stake in Pfizer during the 1st quarter valued at about $28,000. Finally, North Capital Inc. bought a new stake in Pfizer during the 1st quarter valued at about $28,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of PFE stock traded up $0.05 during mid-day trading on Friday, hitting $25.16. The company had a trading volume of 31,819,451 shares, compared to its average volume of 45,227,284. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $30.43. The stock's 50 day moving average price is $24.60 and its 200-day moving average price is $24.44. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company has a market capitalization of $143.05 billion, a P/E ratio of 13.38, a P/E/G ratio of 0.89 and a beta of 0.52.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter in the previous year, the firm earned $0.60 earnings per share. The company's quarterly revenue was up 10.3% compared to the same quarter last year. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be given a dividend of $0.43 per share. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. Pfizer's payout ratio is 91.49%.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. HSBC reduced their price target on shares of Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a research note on Monday, May 19th. Jefferies Financial Group lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st. Leerink Partners reduced their price target on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a research note on Wednesday, April 30th. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target for the company. Finally, Redburn Atlantic reduced their price target on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, five have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.